Trial Profile
A phase I, randomized, placebo-controlled study assessing the safety of Elamipretide in heart failure patients with reduced ejection fraction (HFrEF)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2016
Price :
$35
*
At a glance
- Drugs Elamipretide (Primary)
- Indications Heart failure
- Focus Adverse reactions
- 07 Oct 2016 New trial record